A detailed history of Deep Track Capital, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Deep Track Capital, LP holds 3,750,945 shares of VRDN stock, worth $78.8 Million. This represents 3.15% of its overall portfolio holdings.

Number of Shares
3,750,945
Previous 3,923,849 4.41%
Holding current value
$78.8 Million
Previous $51 Million 67.16%
% of portfolio
3.15%
Previous 1.68%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.16 - $23.33 $2.1 Million - $4.03 Million
-172,904 Reduced 4.41%
3,750,945 $85.3 Million
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $5.43 Million - $8.07 Million
467,796 Added 13.54%
3,923,849 $51 Million
Q1 2024

May 15, 2024

SELL
$17.09 - $23.82 $3 Million - $4.18 Million
-175,675 Reduced 4.84%
3,456,053 $60.5 Million
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $7.43 Million - $15 Million
668,461 Added 22.56%
3,631,728 $79.1 Million
Q3 2023

Nov 14, 2023

BUY
$15.16 - $24.7 $25.5 Million - $41.6 Million
1,683,765 Added 131.6%
2,963,267 $45.5 Million
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $1.11 Million - $1.46 Million
49,243 Added 4.0%
1,279,502 $30.4 Million
Q1 2023

May 15, 2023

SELL
$25.04 - $37.6 $13.5 Million - $20.3 Million
-540,895 Reduced 30.54%
1,230,259 $31.3 Million
Q4 2022

Feb 14, 2023

SELL
$18.78 - $29.74 $3.74 Million - $5.92 Million
-199,136 Reduced 10.11%
1,771,154 $51.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $8.56 Million - $20.4 Million
800,000 Added 68.36%
1,970,290 $40.4 Million
Q1 2022

May 16, 2022

SELL
$16.79 - $20.88 $2.79 Million - $3.47 Million
-166,400 Reduced 12.45%
1,170,290 $21.6 Million
Q4 2021

Feb 14, 2022

BUY
$15.65 - $21.5 $20.9 Million - $28.7 Million
1,336,690 New
1,336,690 $26.4 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $838M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.